Physician profile
Douglas Ball
NPI 1730381625
$579.34
in general payments reported to CMS, 2019-2025
10 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.97 · 2023: $119 · 2024: $325 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $140.43 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $103.79 | 2023-2024 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $78.05 | 2023-2025 | Takhzyro, Glassia, Hyqvia |
| Pharming Healthcare, INC. | $60.70 | 2023-2024 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $58.42 | 2023-2024 | Tezspire, Fasenra |
| Leo Pharma INC. | $42.92 | 2024 | Adbry |
| Blueprint Medicines Corporation | $32.49 | 2023-2024 | Ayvakit |
| Alkermes, INC. | $23.97 | 2019 | |
| Csl Behring | $20.99 | 2025 | Andembry |
| Kaleo, INC. | $17.58 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.